

Conference Program

12th International Charité Mayo Conference

**Global Perspectives and
Future Directions in
Women's Cancer**

**April 26-29, 2023
Berlin**



**Breast Cancer, Ovarian Cancer, Cervical and
Endometrial Cancer, Sarcoma**

**12 HOURS OF LIVE SURGERY
CMC MASTER COURSES
CMC CADAVER COURSES**

www.charite-mayo.de

Frühes
Mammakarzinom

Ovarialkarzinom

LYNPARZA® IN DER ADJUVANZ*

Die erste zielgerichtete
Therapie mit signifikantem
OS-Vorteil^{1,2,*}Beim frühen HER2-negativen
Mammakarzinom mit
BRCA1/2-Keimbahnmutation
und hohem Rezidivrisiko.

LYNPARZA®***,***

Erstmals Langzeitüberleben[#] mit
PARPi in der 1L-Erhaltungstherapie
des fortgeschrittenen OCPAOLA-1 (HRD+): >6 Jahre[†] mOS unter
Lynparza® & BevacizumabPAOLA-1 (HRD+): 75,2 Monate[†] mOS unter Lynparza® & Bevacizumab vs. 57,3 Monate unter Placebo & Bevacizumab[†]

* Lynparza wird angewendet als Monotherapie oder in Kombination mit einer endokrinen Therapie für die adjuvante Behandlung von erwachsenen Patienten mit Keimbahn-BRCA1/2-Mutationen, die ein HER2-negatives Mammakarzinom im Frühstadium mit hohem Rezidivrisiko haben und zuvor mit neoadjuvanter oder adjuvanter Chemotherapie behandelt wurden.⁴ ** Lynparza® Filmtabletten in Kombination mit Bevacizumab werden angewendet zur Erhaltungstherapie von erwachsenen Patientinnen mit einem fortgeschrittenen (FIGO-Stadien III und IV) high-grade epithelialen Ovarialkarzinom, Eileiterkarzinom oder primären Peritonealkarzinom, die nach einer abgeschlossenen Platin-basierten Erstlinien-Chemotherapie in Kombination mit Bevacizumab ein Ansprechen (vollständig oder partiell) haben und deren Tumor mit einem positiven Status der homologen Rekombinations-Defizienz (HRD) assoziiert ist. Der Status HRD-positiv ist definiert entweder durch eine BRCA1/2-Mutation und/oder genomische Instabilität.⁴ *** Lynparza® Filmtabletten als Monotherapie werden angewendet zur Erhaltungstherapie von erwachsenen Patientinnen mit einem fortgeschrittenen (FIGO-Stadien III und IV) BRCA1/2-mutierten (in der Keimbahn und/oder somatisch), high-grade epithelialen Ovarialkarzinom, Eileiterkarzinom oder primären Peritonealkarzinom, die nach einer abgeschlossenen Platin-basierten Erstlinien-Chemotherapie ein Ansprechen (vollständig oder partiell) haben.⁴

1L: Erstlinie; **mOS:** Medianes Gesamtüberleben; **OC:** Ovarialkarzinom; **PARPi:** Poly(ADP-ribose)-Polymerase-Inhibitor; **gBRCA1/2m:** BRCA1/2-Keimbahnmutation; **HER2:** Humaner-Epidermal-Wachstumsfaktor-Rezeptor 2; **HR:** Hormonrezeptor; **iDFS:** Invasives krankheits-freies Überleben; **OS:** Gesamtüberleben. * OS unter Lynparza® vs. Placebo: 89,8 % vs. 86,4 % (HR = 0,68; 98,5%-KI: 0,47–0,97; p=0,009) innerhalb von 4 Jahren. Die OS-Ergebnisse stammen vom Datenschnittpunkt 2, einer vordefinierten Interimsanalyse mit einem medianen Follow-up von 3,5 Jahren in der Gesamtpopulation.^{1,2} # S3-Leitlinie definiert Langzeitüberleben als ≥ 5 Jahre Krankheitsdauer nach Erstdiagnose.⁵ † Median instabil, < 50 % Datenreife.

1 Geyer CE et al. Ann Oncol 2022; 33(12): 1250–1268 (inkl. ergänzendem Anhang) **2** Tutt ANJ et al. Mündliche Präsentation. Präsentiert auf der virtuellen Plenarsitzung des ESMO 2022, 16.–17. März 2022. Abstract VP1-2022 **3** Ray-Coquard I et al. ESMO 2022 Paris; Abstract LBA29 **4** Fachinformation Lynparza® 100 mg/150 mg Filmtabletten, Stand 01/2023 **5** Leitlinienprogramm Onkologie: S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren, Version 5.1. AWMF-Leitlinien-Register Nr. 032/0350L (Stand 05/2022).

Lynparza® 100 mg Filmtabletten, Lynparza® 150 mg Filmtabletten

Wirkstoff: Olaparib. Verschreibungspflichtig. **Zus.:** Jede 100-mg-Filmtablette enth. 100 mg Olaparib. Jede 150-mg-Filmtablette enth. 150 mg Olaparib.

Sonst. Bestandt.: Tablettenkern: Copovidon, Hochdisperses Siliciumdioxid, Mannitol (Ph.Eur.), Natriumstearylfumarat (Ph.Eur.). Tablettenüberzug: Hypromellose, Macrogol (400), Titandioxid (E171), Eisen(III)-hydroxid-oxid x H₂O (E172), Eisen(II,III)-oxid (E172) (nur 150 mg Tabletten). **Anw.:** Ovarialkarzinom: Lynparza wird angewendet als Monoth. für d.: – Erhaltungsth. v. erw. Patientinnen mit e. fortgeschritt. (FIGO-Stadien III u. IV) BRCA1/2-mutierten (in d. Keimbahn u./od. somatisch), high-grade epithelialen Ovarialkarzinom, Eileiterkarzinom od. primären Peritonealkarzinom, d. nach e. abgeschl. Pt-basierten Erstlinien-Chemoth. e. Ansprechen (vollst. od. partiell) haben. – Erhaltungsth. v. erw. Patientinnen mit e. Pt-sensitiven Rezidiv e. high-grade epithelialen Ovarialkarzinoms, Eileiterkarzinoms od. primären Peritonealkarzinoms, d. auf e. Pt-basierte Chemoth. ansprechen (vollst. od. partiell). Lynparza in Komb. mit Bevacizumab wird angewendet für d.: – Erhaltungsth. v. erw. Patientinnen mit e. fortgeschritt. (FIGO-Stadien III u. IV) high-grade epithelialen Ovarialkarzinom, Eileiterkarzinom od. primären Peritonealkarzinom, d. nach e. abgeschl. Pt-basierten Erstlinien-Chemoth. in Komb. mit Bevacizumab e. Ansprechen (vollst. od. partiell) haben u. deren Tumor mit e. positiven Status d. homologen Rekombinations-Defizienz (HRD) assoziiert ist. D. Status HRD-positiv ist definiert entweder durch e. BRCA1/2-Mutation u./od. genomische Instabilität. Mammakarzinom: Lynparza wird angewendet als: – Monoth. od. in Komb. mit e. endokrinen Therapie für d. adjuvante Behandl. v. erw. Patienten mit Keimbahn-BRCA1/2-Mutationen, d. e. HER2-negatives Mammakarzinom im Frühstadium mit hohem Rezidivrisiko haben u. zuvor mit neoadjuvanter od. adjuvanter Chemoth. behandelt wurden. – Monoth. für d. Behandl. v. erw. Patienten mit BRCA1/2-Mutationen in d. Keimbahn, d. e. HER2-negatives, lokal fortgeschritt. od. metastasiertes Mammakarzinom haben. D. Patienten sollten zuvor mit e. Anthrazyklin u. e. Taxan im (neo)adjuvanten od. metastasierten Setting behandelt worden sein, es sei denn, d. Patienten waren für d. Behandl. nicht geeignet. Patienten mit Hormonrezeptor (HR)-positivem Mammakarzinom sollten außerdem e. Krankheitsprogression während od. nach e. vorherigen endokrinen Therapie aufweisen od. für e. endokrine Therapie nicht geeignet sein. Adenokarzinom d. Pankreas: Lynparza wird angewendet als Monoth. für d. Erhaltungsth. v. erw. Patienten mit Keimbahn-BRCA1/2-Mutationen, d. e. metastasiertes Adenokarzinom d. Pankreas haben u. d. Erkrank. nach e. mind. 16-wöchigen Pt-haltigen Behandl. im Rahmen e. Erstlinien-Chemoth. nicht progredient war. Prostatakarzinom: Lynparza wird angewendet: – als Monoth. für d. Behandl. v. erw. Patienten mit mCRPC u. BRCA1/2-Mutationen (in d. Keimbahn u./od. somatisch), d. Erkrank. nach vorheriger Behandl. d. e. neue hormonelle Substanz umfasste, progredient ist. – in Komb. mit Abirateron u. Prednison od. Prednison für d. Behandl. v. erw. Patienten mit mCRPC, bei denen e. Chemoth. nicht klinisch indiziert ist. **Gegenanz.:** Überempfindlichkeit gegen d. Wirkstoff od. e. sonstig. Bestandt., Stillen während d. Behandl. u. 1 Monat nach Einnahme d. letzten Dosis. **Nebenw.:** Möglicherweise dringend ärztl. Behandl. ist erforderlich bei folgenden Nebenw.: *Sehr häufig:* Anämie. Gelegentl.: Allergische Reakt., Dermatitis, myelodysplastisches Syndr. od. akute myeloische Leukämie. Andere Nebenw. sind: *Sehr häufig:* Übelkeit, Erbrechen, Fatigue (einschließlich Asthenie), Dyspepsie, vermind. Appetit, Kopfschmerzen, Dysgeusie, Schwindel, Husten, Dyspnoe, Diarrhö, Leukopenie, Neutropenie. *Häufig:* Hautausschlag, Stomatitis, Schmerzen im Oberbauch, venöse Thromboembolie, Lymphonödie, Thrombozytopenie, Anstieg d. Kreatininwertes im Blut. *Gelegentl.:* Erhöhung d. mittleren korpuskulären Volumens. *Selten:* Angiodödem, Erythema nodosum. **Weitere Hinw.:** s. Fachinformation. **Pharmazeutischer Unternehmer:** AstraZeneca GmbH; Friesenweg 26, 22763 Hamburg. E-Mail: azinfo@astrazeneca.com, www.astrazeneca.de, Servicehotline für Produktanfragen: 0800 22 88 660. **Stand:** 01/2023. DE-54613/2023

SUPPORTERS 4

GREETING WORDS | LOOKING BACK 5

SCIENTIFIC PROGRAM

WEDNESDAY, APRIL 26, 2023 8

THURSDAY, APRIL 27, 2023 10

FRIDAY, APRIL 28, 2023 14

SATURDAY, APRIL 29, 2023 18

SPEAKERS, CHAIRS, SURGEONS, MODERATORS 20

GENERAL INFORMATION 22

WHAT'S MORE 24

TRAVEL AND ACCOMMODATION 25

SPONSORS 26

COMING UP 30

HIGHLIGHTS 2023

LIVE SURGERY:
WED, THU, FRI – 12 HRS IN TOTAL!
THE MODERATORS IN LECTURE HALL WILL FORWARD YOUR
QUESTIONS TO THE SURGEONS!

CMC MASTER COURSES:
DAILY
EACH ONE WITH A DIFFERENT SUBJECT AREA


CMC CADAVER COURSES:
2 ON SATURDAY
GYNECOLOGIC ONCOLOGY AND BREAST CANCER



SUPPORTERS

 <p>IGCS INTERNATIONAL GYNECOLOGIC CANCER SOCIETY</p>	 <p>Endorsed by ESGO</p>	 <p>ENGOT European Network of Gynaecological Oncological Trial groups</p>
 <p>GCIG GYNECOLOGIC CANCER INTERGROUP</p>	 <p>AGO ARBEITSGEMEINSCHAFT GYNÄKOLOGISCHE ONKOLOGIE E.V.</p>	 <p>TOC</p>
 <p>PARSGO The Pan-Arabian Research Society of Gynecological Oncology</p>	 <p>NOGGO e.V. Nord-Deutsche Gesellschaft für Gynäkologische Onkologie e.V.</p>	 <p>Deutsche Stiftung Eierstockkrebs German Ovarian Cancer Foundation</p>
 <p>Forum Gynäkologische Onkologie</p>	 <p>COGI <i>All about Women's Health</i></p>	 <p>NESA NEW EUROPEAN SURGICAL ACADEMY</p>
 <p>cancers an Open Access Journal by MDPI</p>	 <p>Europäische Künstlergilde für Medizin und Kultur</p>	 <p>esanum</p>
 <p>BERLIN BERLIN PARTNER für Wirtschaft und Technologie</p>	 <p>VISIT BERLIN</p>	 <p>EUROPÄISCHE UNION Europäischer Fonds für regionale Entwicklung</p>

*) This project is co-financed by the European Regional Development Fund



CONFERENCE CHAIRS, SCIENTIFIC BOARD

Prof. Dr. med. Dr. h.c. Jalid Sehoul
Department of Gynecology with Center for
Oncological Surgery

Prof. Dr. med. Jens-Uwe Blohmer
Department of Gynecology and Breast Center
Charité - Universitätsmedizin Berlin

Dear Colleagues,

It is our pleasure to invite you to our traditional 12th International Charité Mayo Conference in Berlin: "Global Perspectives and Future Directions in Women's Cancer".

We are so proud to relaunch our prestigious meeting with its original and unique format what was founded in 1996.

After three years of COVID-19-related online meetings, we now return to the old familiar form of face-to-face meetings, so that personal contact for collegial exchange, networking and in particular discussion of the latest topics in women's health are possible again.

The conference will feature the hottest topics in gynecological oncology including 12 hours of live surgeries, debates, exclusive master workshops and international panel discussions.

We are convinced that this extraordinary dialogue between international experts and the participants will significantly impact clinical routine and the future of women's cancer management.

We would be very pleased to welcome you personally in the heart of Europe to bring new and substantial impact on the scientific community and clinical practice.

Sincerely yours,

Prof. Dr. Jalid Sehoul

Prof. Dr. Jens-Uwe Blohmer

GREETING WORDS



Prof. Dr. Martin E. Kreis
Chief Medical Officer
Charité - Universitätsmedizin Berlin

Dear Colleagues:

Welcome to the 12th International Charité Mayo Conference (CMC)!

The CMC hosts and planning teams have put together a truly outstanding and stimulating program comprising cutting-edge research and high-end clinical care. In addition to bringing together experts in the field of Gynecological Oncology from all over the world, the conference will help to improve high-level patient care, women's health, and - in particular - the management of gynecologic cancers.

Mayo Clinic and Charité are proud to be ranked #1 and #5 respectively in the Newsweek list of the world's best hospitals. With this joint conference, these two highly prestigious institutions intend to widen their impact, creating a transatlantic exchange that will function as a bridge to truly global reach. Ideally, the effects of this endeavor will extend beyond the ranks of researchers and clinicians, and serve to inspire people in both the U.S. and Germany.

The Executive Committee of Charité - Universitätsmedizin Berlin takes great pride in supporting this prestigious international event. We are grateful to the planning teams for their valuable work. Conference attendees can look forward to interesting exchanges, new insights and - for those coming to Berlin - a fantastic stay in this vibrant city.

Sincerely yours,

A handwritten signature in black ink, appearing to be 'M. Kreis', written in a cursive style.

Prof. Dr. Martin E. Kreis



Prof. Dr. Karl Lauterbach
Federal Minister of Health
Member of the German Parliament

The scientific exchange at the 12th International Charite Mayo Conference will set new Standards for the treatment of gynaecological cancers. It will have a lasting impact on the survival and quality of life of female cancer patients worldwide. I thank all participants for their valuable work and wish you all every success!

Prof. Dr. Karl Lauterbach

LOOKING BACK: FACTS AND FIGURES

2021

11 th International Charité Mayo Conference

May 5-8, 2021, online live from Berlin

> 2,400	87	7	95	36	15	1.8 Mio
Participants	Countries watching	Main Topic Blocks	Speakers	Sponsors	Cooperation Partners	Social Media Reach

2022

CMC DISTILLED

April 9, 2022, online live from Berlin

> 1,700	100	3	48	18	16	1.6 Mio
Participants	Countries watching	Main Topic Blocks	Speakers	Sponsors	Cooperation Partners	Social Media Reach

WEDNESDAY, APRIL 26, 2023 BREAST CANCER

08.20 am **Welcome Address of the Hosts and Greeting Words**
J.-U. Blohmer and J. Sehoul

08.30 am **LIVE SURGERY**
NSME, BCS, IOUS, SNB, Autologous and Allogenic Reconstructions, Lipofilling
Moderation: F. Rey, M. Karsten
Surgeons: J.-U. Blohmer, O. Camara, J. Wagner, J. Kricheldorf, R. Reinemer, S. Paepke

DURING LIVE SURGERY:
The Most Challenging Case of the Year
J. K. Wagner

12.30 pm **Lunch Break**

01.00 pm **SYMPOSIUM** (With kind support of AstraZeneca)
Paradigm Shift in Breast Cancer?
Chair: J.-U. Blohmer

- ▶ **BRCAm Tumours - The Next Subtype?**
D. Speiser
- ▶ **New Approaches in Metastatic Breast Cancer - HER2-Low and HR-Positive**
J.-U. Blohmer
- ▶ **Q&A**

PRESIDENTIAL LECTURES

Chairs: D. Speiser, F. Rey

01.50 pm **New Strategies for Management of Patients with ER+/HER2- Breast Cancer and Progression on CDK 4/6 Inhibitors: From Targeted Therapies to ADC**
M. P. Goetz

02.10 pm **Do We Need More Technologies in Breast Surgery and Breast Reconstruction Like OPS, TAD, TAS, ICG-A, Synthetic Meshes, ADMs?**
J.-U. Blohmer

STATE OF THE ART SESSION

Chairs: R. Leon Ferre, S. Kümmel

02.30 pm **Precision Surgery in Breast Cancer - Visualizing Breast Tumor Placement and Extent**
F. Rey

02.50 pm **Hereditary Breast Cancer - Treatment of Early and Advanced Breast Cancer**
D. Speiser

READY FOR PRIME TIME?

Chairs: V. Kiver, T. Haddad, D. Kaul

03.10 pm **Alarmbased PRO Monitoring - Ready for Clinical Implementation for All?**

M. Karsten

03.30 pm **Conventional Versus Hypofractionated Post-Mastectomy Proton Radiotherapy in HR-Deficient Tumors**

R. Mutter

03.50 pm Coffee Break

IMPORTANT AND ACTUAL QUESTIONS AND TOPICS

Chairs: M. P. Goetz, J.-U. Blohmer

04.20 pm **De-Escalation of Therapy in the Elderly Necessary and Possible?**

A. Lee

04.35 pm **Moving Clinical Trials to Home: Home-Based Care**

T. Haddad

04.50 pm **Patient-Derived Xenografts and/or Cancer Genom Sequence: Ready for Clinical Practice?**

V. Kiver

05.05 pm **What is Low-HER2 and Does it Matter in Clinical Decision?**

S. Kümmel

05.20 pm **New Strategies in the Neoadjuvant and Metastatic Setting for Triple-Negative Breast Cancer**

R. Leon Ferre

05.35 pm **New Models to Understand Unique Biology and Treatment Response in Invasive Lobular Carcinoma**

S. Oesterreich

05.50 pm **Development of a Breast Cancer Vaccine for Primary Prevention of Breast Cancer**

K. Knutson

06.05 pm **Discussion**

all speakers

06.30 pm End of Program

04.00 to 06.00 pm PARALLEL TO MAIN PROGRAM

CMC MASTER COURSE

Surgical and Medical Management in Ovarian Cancer

J. Sehouli, S. Dowdy, C. Fotopoulou



THURSDAY, APRIL 27, 2023

CERVICAL, ENDOMETRIAL CANCER, SARCOMA

08.30 am **LIVE SURGERY**

Sentinel Node, Radical Hysterectomy, Nerve-Sparing Techniques, ICG Techniques, Perioperative Management, Exenteration
Moderation: A. Mariani, G. Glaser, A. Mustea, J. Sehouli (Plenary); R. Armbrust (Operating Room)
Surgeons: M. Z. Muallem, V. Chiantera, G. Aletti, E. Delarue

DURING LIVE SURGERY:

The Most Challenging Case of the Year
A. Kumar

12.30 pm Lunch Break

- 01.00 pm **COLLOQUIUM** (Fully funded by Eisai Europe Ltd.*)
Priming and Practical Optimal Management Before, During and After Immunotherapy in Endometrial Cancer
- ▶ **Distillation of Current Standard of Care in Immunotherapy**
N. Concin
 - ▶ **How to Prepare Patients Before Therapy?**
J. Sehouli
 - ▶ **How to Monitor Patients During Therapy?**
B. Monk
 - ▶ **Long-term Survivors in Endometrial Cancer - Who They Are**
R. Coleman
 - ▶ **Panel Discussion**
N. Concin, B. Monk, R. Coleman, J. Sehouli

CERVICAL CANCER

Chairs: K. Pietzner, S. Dowdy, W. Lichtenegger

PRESIDENTIAL LECTURE

- 01.50 pm **How to Treat Best Advanced and Metastatic Cervical Cancer**
D. Cibula

*) Eisai has had no influence on its scientific content or choice of faculty.

OVERVIEW

- 02.10 pm **Best of Global Clinical Trials: Current and Planned Studies**
E. Roser
- 02.15 pm **CMC Exclusive! First Scientific Presentation: Charité Experience Regarding Alustents**
J. Neymeyer, R. Armbrust

PRO/CON DEBATE

- 02.20 pm **Open Versus Minimally Invasive Surgery in Cervical Cancer: Where are We Now After 5 Years of LACC?**
▶ **Open Surgery**
C. Marth
▶ **Minimally Invasive Surgery**
G. Scambia
Discussion
M. Z. Muallem, C. Marth, G. Scambia
- 03.00 pm Coffee Break

ENDOMETRIAL CANCER, SARCOMA

Chairs: A. Mariani, R. Chekerov, D. Lorusso

PRESIDENTIAL LECTURE

- 03.30 pm **New Standards in Advanced and Metastatic Endometrial Cancer**
M. R. Mirza

OVERVIEW

- 03.50 pm **Best of Global Clinical Trials: Current and Planned Studies**
T. Arndt

DEBATE

- 04.00 pm **Sentinel Node Biopsy**
▶ **Who Should Get It?**
N. Abu-Rustum
▶ **Who Not?**
A. Mariani
Discussion

Endometriumkarzinom

comprehensive – tailored – on demand

Am Ball bleiben beim Endometriumkarzinom!

Mittwoch, 10.05.2023

15:30 – 19:00 Uhr als Live-Stream



Jetzt über Scan des QR-Codes
oder www.eisaioncademy.de/ec
für die Veranstaltung registrieren



Die Eisai GmbH versichert, dass die Inhalte der Fortbildungsmaßnahme produkt- und dienstleistungsneutral gestaltet sind. Potentielle Interessenskonflikte des Veranstalters, der wissenschaftlichen Leitung und der Referenten werden während der Veranstaltung in einer Selbstausskunft gegenüber den Teilnehmern offengelegt. Die Gesamtaufwendungen der Veranstaltung belaufen sich auf 30.830 €. Es gibt keine weiteren Sponsoren.

Die Einladung für diese von der Eisai GmbH organisierte Online-Fortbildungsveranstaltung kann nur für fachliche Teilnehmer ausgesprochen werden. Bitte beachten Sie, dass Sie für eine Teilnahme an der Veranstaltung von mehr als 90 Minuten eine Dienstherrengenehmigung benötigen. Das Formular hierfür erhalten Sie nach der Anmeldung per Mail. Sollten bei der Registrierung Probleme auftreten, wenden Sie sich bitte per Email an registrierung@eisaioncademy.de



HOTTEST TOPICS IN CLINICAL ROUTINE AND RESEARCH

- 04.40 pm **Newest Insights of Robotic Assisted Surgery in Endometrial Cancer**
M. Z. Muallem
- 05.00 pm **Consequence for Clinical Day and Science: Checkpoint Inhibitor after Checkpoint Inhibitor - Who Benefits, Who Not, How to Modify the Therapy?**
D. Lorusso
- 05.20 pm **Molecular Characterization in Endometrial Cancer: What are the Definitions, What are the Limitations?**
E. Taube
- 05.40 pm **What is the Best Therapy for Wild-Type and Mutant P53 Tumors?**
J. Sehouli
- 06.00 pm **Dostarlimab Plus Chemotherapy for the Treatment of Primary Advanced or Recurrent (A/R) Endometrial Cancer (EC): A Placebo (PBO)-Controlled Randomised Phase 3 Trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)**
L. Hanker
- 06.20 pm **Discussion**
all speakers
- 06.30 pm **End of Program**

04.00 to 06.00 pm PARALLEL TO MAIN PROGRAM

CMC MASTER COURSE

Surgical and Topographic Anatomy: Breast Cancer and Reconstructive Surgery

J.-U. Blohmer, O. Camara, S. Paepke, F. Reyat

CMC HONORARY EVENT

**Berlin, Graz, Rochester, Tokio -
The Global Dialogue**

Start: 7.30 pm

More information on page 24

Participation only by invitation!

FRIDAY, APRIL 28, 2023 OVARIAN CANCER

08.30 am **LIVE SURGERY**

En-bloc Resection, Peritonectomy, Nerve-Sparing Techniques, Lymph Node Dissection, ICG Techniques, Perioperative Management
Moderation: S. Dowdy, T. Herzog, C. Marth (Plenary);
R. Armbrust (Operating Room)
Surgeons: C. Fotopoulou, J. Sehouli, P. Harter,
R. Chekerov, C. Beteta

DURING LIVE SURGERY:

The Most Challenging Case of the Year
A. Miranda

12.30 pm Lunch Break

01.00 pm **SYMPOSIUM** (With kind support of GlaxoSmithKline) **Rethinking Ovarian Cancer Treatment - From Ideas to Practice. Where are we Today? What are New Concepts for Tomorrow?**

Chair: P. Harter

▶ **Brief Introduction**

P. Harter

▶ **Surgery - Challenging Optimal Timing**

P. Wimberger

▶ **Chemotherapy - Challenging Historical Paradigms**

K. Pietzner

▶ **Maintenance Therapy - Rethinking the Backbone**

J. Sehouli

▶ **Summary**

P. Harter

OVARIAN CANCER I

Chairs: C. Marth, A. Wahner-Hendrickson, M.R. Mirza

PRESIDENTIAL LECTURE

- 01.50 pm **How to Treat Best Advanced Ovarian Cancer?**
T. Herzog

OVERVIEW

- 02.10 pm **Best of Global Clinical Trials: Current and Planned Studies**
R. Armbrust
- 02.15 pm **CMC Exclusive! First Scientific Presentation: 20 Years Experience in Ovarian Cancer Surgery - Charité Berlin**
J. Sehouli

HOTTEST TOPICS IN CLINICAL ROUTINE AND RESEARCH

- 02.20 pm **What Can HRD Testing Really Predict, What Not?**
S. Weroha
- 02.40 pm **Real-World Evidence in Advanced Ovarian Cancer and its Clinical Implication**
J. Sehouli
- 03.00 pm **Current and Future Options for Patients with Relapsed Ovarian Cancer**
A. Wahner-Hendrickson
- 03.20 pm **Newest Insights of Immunotherapy in Gynecological Malignancies**
B. Monk
- 03.40 pm Coffee Break

SCIENTIFIC PROGRAM

OVARIAN CANCER II

Chairs: J. Sehouli, C. Fotopoulou, S. J. Weroha

LECTURES

- 04.10 pm **HIPEC, PIPAC and More - Where is their Real Place?**
P. Harter
- 04.30 pm **Surgical and Conservative Management of Bowel Obstruction in Ovarian Cancer**
C. Fotopoulou
- 04.50 pm **Secondary Malignancies: How to Prevent, How to Treat Best?**
L. Bullinger
- 05.10 pm **PARP After PARP Therapy: Who Can Really Benefit, Who Not?**
J. Ledermann
- 05.30 pm **Endometriosis-associated Ovarian Cancer and its Clinical Implications**
S. Mechsner
- 05.50 pm **Discussion**
all speakers
- 06.00 pm End of Program

05.30 to 07.30 pm PARALLEL TO MAIN PROGRAM

CMC MASTER COURSE

Prerehabilitation, ERAS, Minimally Invasive Complication Management, Blood Management

S. Dowdy, A. Kumar, J. Sehouli, M. Lee, M. G. Inci-Turan, F. Büttner



CMC NIGHT AT THE MUSEUM OF NATURAL HISTORY: SPECIAL DINNER AND MORE

Start: 8.00 pm

More information on page 24



DO NOT MISS THE POSTER EXHIBITION!

2ND FLOOR OF THE LANGENECK-VIRCHOW-HAUS

Topics:

Breast cancer

Ovarian cancer

Cervical cancer

Uterine cancer including sarcoma

Vulvar and vaginal cancer

Rare tumors and gestational trophoblastic neoplasia

Surgical techniques and preoperative management

Symptom management and palliation

Gynecologic pathology and disease pathogenesis

Predictive and prognostic biomarkers

Basic and translational science

POSTER SESSION

SATURDAY, APRIL 29, 2023

during the Lunch Break (starting 1.00 pm)

POSTER AWARDS

The three best posters will be awarded (EUR 500 each)!

Winners will be announced in the Closing Session on

Saturday, April 29, 2023, starting at 4.00 pm.

ABSTRACT PUBLICATION

The accepted abstracts will be published as supplement of the Anticancer Research Journal.

ANTICANCER RESEARCH

SATURDAY, APRIL 29, 2023

GLOBAL HEALTH AND MOLECULAR DIAGNOSTICS AND PERSONALIZED THERAPIES IN ALL WOMEN'S CANCERS

Chairs: E. I. Braicu, G. Konecny

INSIGHTS OF GLOBAL HEALTH PROGRAMS

**09.00 am 80 Minutes Around the World: Cervical Cancer
Elimination Between Vision and Reality**
S. Nasser, M. Gültekin, A. Ullrich, A. Stepanyan

International Charité Mayo Award for Outstanding
Engagement in Gynecological Oncology

10.20 am Award Lecture:
The Never-Ending HER2 Study
D. Slamon



OVERVIEW

10.50 am Best of Clinical Trials in Rare Tumors
J. Grabowski

11.00 am Coffee Break

Chairs: J. Sehouli, J.-U. Blohmer, A. Wahner-Hendrickson

INSIGHTS OF CLINICAL DEBATES

11.30 am What is PARP Resistance and How to Overcome?
E. I. Braicu

LECTURES

11.50 am Antibody Drug Conjugate (ADC)

▶ **Breast Cancer**

J.-U. Blohmer

▶ **Gynecological Cancer**

P. Harter

Discussion

J. Sehouli, J.-U. Blohmer, M. Beck, P. Harter

**12.30 pm Evolution of Synchronous Bilateral Breast Cancers
Provide Insights into Interactions Between Host,
Tumor and Immunity**
F. Reyat

12.45 pm Digital Patient
T. Pross

01.00 pm Lunch Break

DURING LUNCH BREAK

POSTER SESSION

G. Konecny, K. Pietzner, C. Flethe and more



- 02.00 pm **SYMPOSIUM** (With kind support of GlaxoSmithKline)
Advancing Endometrial Cancer Treatment - Ongoing Developments and Growing Relevance of Biomarker Testing
- ▶ **The Growing Relevance of Upfront Biomarker Testing at Diagnosis of Endometrial Cancer**
X. Matias-Guiu
 - ▶ **Current Developments in the Treatment of Advanced/Recurrent Endometrial Cancer**
M.R. Mirza

Chairs: J. Sehouli, J.-U. Blohmer, A. Wahner-Hendrickson

LECTURES

- 02.50 pm **Study Update GOG and ENGOT: Clinical Trial Landscape in GOG-ENGOT Collaboration**
R. Coleman
- 03.10 pm **Learning Lessons From Long-Term Survivors with Gynecological Cancer**
H. Woopen
- 03.30 pm **MOLECULAR TUMOR CONFERENCE**
E.I. Braicu

CLOSING SESSION

- 04.00 pm **Awarding of the Three Best Posters**
- 04.20 pm **Closing Words and Farewell**
- 04.30 pm **End of Program**

09.00 to 11.00 am PARALLEL TO MAIN PROGRAM

CMC MASTER COURSE

Urological Complication Management in Gynecological Oncology

J. Neymeyer, R. Chekerov

08.00 am to 12.00 noon PARALLEL TO MAIN PROGRAM

CMC CADAVER COURSE

Gynecologic Oncology

M.Z. Muallem, A. Miranda, T. Jöns

FULLY BOOKED



01.00 pm to 5.00 pm PARALLEL TO MAIN PROGRAM

CMC CADAVER COURSE

Breast Cancer

J.-U. Blohmer, O. Camara, T. Jöns

LIMIT:
20 PAX

SPEAKERS, CHAIRS, SURGEONS, MODERATORS

Abu-Rustum, Prof. Dr. Nadeem, New York, NY (USA)
Aletti, Prof. Dr. Giovanni, Milan (I)
Armbrust, Dr. med. Robert, Berlin (D)
Arndt, Dr. med. Tjadina, Berlin (D)
Beck, Dr. med. Maximilian, Berlin (D)
Beteta, Dr. med. Carmen, Berlin (D)
Blohmer, Prof. Dr. med. Jens-Uwe, Berlin (D)
Braicu, Prof. Dr. med. Elena Ioana, Berlin (D) + Palo Alto (USA)
Büttner, Dr. med. Franziska, Berlin (D)
Bullinger, Prof. Dr. med. Lars, Berlin (D)
Camara, PD Dr. med. Oumar, Gotha (D)
Chekerov, PD Dr. med. Radoslav, Berlin (D)
Chiantera, Prof. Dr. Vito, Naples (I)
Cibula, Prof. Dr. David, Prague (CZ)
Coleman, Dr. Robert L., The Woodlands, TX (USA)
Concin, Prof. Dr. med. Nicole, Innsbruck (A) + Essen (D)
Delarue, Dr. med. Eleonore, Berlin (D)
Dowdy, Prof. Dr. Sean C., Rochester, MN (USA)
Flethe, Chiara, Berlin (D)
Fotopoulou, Prof. Dr. med. Christina, Berlin (D) + London (UK)
Glaser, Dr. Gretchen, Rochester, MN (USA)
Goetz, Prof. Dr. Matthew P., Rochester, MN (USA)
Grabowski, PD Dr. med. Jacek, Berlin (D)
Gültekin, Prof. Dr. Murat, Ankara (TR)
Haddad, Dr. Tufia C., Rochester, MN (USA)
Hanker, Prof. Dr. med. Lars, Lübeck (D)
Harter, Prof. Dr. med. Philipp, Essen (D)
Herzog, Prof. Dr. Thomas, Cincinnati, OH (USA)
Inci-Turan, PD Dr. med. Melisa Gülhan, Bonn (D)
Jöns, PD Dr. Thomas, Berlin (D)
Karsten, Dr. med. Maria, Berlin (D)
Kaul, PD Dr. David, Berlin (D)
Kiver, Dr. med. Verena, Berlin (D)
Knutson, Prof. Dr. Keith L., Jacksonville, FL (USA)
Konecny, Prof. Dr. Gottfried E., Los Angeles, CA (USA)
Kricheldorf, Dr. med. Julian, Berlin (D)
Kumar, Dr. Amanika, Rochester, MN (USA)
Kümmel, Prof. Dr. med. Sherko, Essen (D)
Ledermann, Prof. Dr. Jonathan A., London (UK)

SPEAKERS, CHAIRS, SURGEONS, MODERATORS

Lee, Dr. Adrian, Pittsburgh, PA (USA)
Lee, Marlene, Berlin (D)
Leon Ferre, Dr. Roberto A., Rochester, MN (USA)
Lichtenegger, Prof. Dr. med. Werner, Berlin (D)
Lorusso, Dr. Domenica, Rome (I)
Mariani, Prof. Dr. Andrea, Rochester, MN (USA)
Marth, Prof. Dr. med. Christian, Innsbruck (A)
Matias-Guiu, Prof. Dr. Xavier, Barcelona (E)
Mechsner, Prof. Dr. med. Sylvia, Berlin (D)
Miranda, Dr. Andrea, Berlin (D)
Mirza, Dr. Mansoor Raza, Copenhagen (DK)
Monk, Prof. Dr. Bradley, Phoenix, AZ (USA)
Muallem, Prof. Dr. med. Dr. med. (syr) Mustafa Zelal, Berlin (D)
Mustea, Prof. Dr. med. Dr. h.c. Alexander, Bonn (D)
Mutter, Dr. Robert, Rochester, MN (USA)
Nasser, Dr. MRCOG Sara, Berlin (D)
Neymeyer, Dr. med. Jörg, Berlin (D)
Oesterreich, Prof. Dr. Steffi, Pittsburgh, PA (USA)
Paepke, Dr. med. Stefan, München (D)
Pietzner, Prof. Dr. med. Klaus, Berlin (D)
Podratz, Prof. Dr. Karl C., Rochester, MN (USA)
Pross, Dr. med. Therese, Berlin (D)
Reinemer, Dr. med. Raphael, Berlin (D)
Reyal, Prof. Dr. Fabien, Paris (F)
Roser, Dr. med. Eva, Berlin (D)
Scambia, Prof. Dr. Giovanni, Rome (I)
Sehouli, Prof. Dr. med. Dr. h.c. Jalid, Berlin (D)
Slamon, Prof. Dr. Dennis J., Santa Monica, CA (USA)
Speiser, Prof. Dr. med. Dorothee, Berlin (D)
Stepanyan, Prof. Dr. Artem, Yerevan (AM)
Taube, Dr. med. Eliane, Berlin (D)
Ullrich, Dr. med. Andreas, Berlin (D)
Wagner, Dr. med. Jenny Katharina, Berlin (D)
Wagner, Dr. med. Juri, Berlin (D)
Wahner-Hendrickson, Dr. Andrea E., Rochester, MN (USA)
Weroha, Dr. Saravut John, Rochester, MN (USA)
Wimberger, Prof. Dr. med. Pauline, Dresden (D)
Wooten, Dr. med. Hannah, Berlin (D)

GENERAL INFORMATION

DATE

April 26-29, 2023

VENUE

Berlin, Germany

Langenbeck-Virchow-Haus

Luisenstraße 58/59, 10117 Berlin, Germany

CONFERENCE CHAIRS, SCIENTIFIC BOARD

Prof. Dr. med. Dr. h.c. Jalid Sehouli

Department of Gynecology with Center for Oncological Surgery,
Charité - Universitätsmedizin Berlin,
Campus Virchow-Klinikum

Prof. Dr. med. Jens-Uwe Blohmer

Department of Gynecology and Breast Center,
Charité - Universitätsmedizin Berlin,
Campus Charité Mitte

CONFERENCE ORGANIZER, INFORMATION

Jörg Eickeler

Beratung · Organisation · Veranstaltung

Neanderstraße 20, 40233 Düsseldorf, Germany

Tel. +49 (0)211 / 688 150 - 0 (Fax: - 50)

info@eickeler.org, www.eickeler.org

ORGANIZING COMMITTEE

Prof. Dr. med. Dr. h.c. Jalid Sehouli

Prof. Dr. med. Jens-Uwe Blohmer

Prof. Dr. med. Elena Ioana Braicu

PD Dr. med. Radoslav Chekerov

Prof. Dr. med. Christina Fotopoulou

Prof. Dr. med. Dr. (syr) Mustafa Zelal Muallem

Prof. Dr. med. Klaus Pietzner

Berlin, Germany

Prof. Dr. William A. Cliby

Prof. Dr. Sean C. Dowdy

Prof. Dr. Matthew P. Goetz

Prof. Dr. Andrea Mariani

Rochester, MN, USA



STEERING COMMITTEE

Prof. Dr. Bradley Monk

Phoenix, AZ, USA

Dr. Mansoor Raza Mirza

Copenhagen, Denmark

ACCREDITATION BY THE MEDICAL ASSOCIATION BERLIN

6 CME Points daily for the main program

5 CME Points in addition for each Cadaver Course (SAT)

WEBSITE

www.charite-mayo.de

REGISTRATION

Online registration

at www.charite-mayo.de → Registration

PARTICIPATION FEES

Total Fee

(main program: 4 days)

EUR 400

EUR 300 for members of AGO, ESGO, NOGGO or PARSGO
as well as Assistant Physicians

EUR 100 for participants from middle- or low-income countries

EUR 50 for Medical Students

Day Ticket

(main program: fee per day)

EUR 160

EUR 130 for members of AGO, ESGO, NOGGO or PARSGO
as well as Assistant Physicians

CMC Master Courses

(extra charge, only in combination with a conference ticket)

EUR 80 Ovarian Cancer | WED, April 26

EUR 80 Breast Cancer | THU, April 27

EUR 80 Preresehabilitation, ERAS | FRI, April 28

EUR 80 Urological Complication Management | SAT, April 29

CMC Cadaver Courses

(extra charge, only in combination with a conference ticket)

EU FULLY BOOKED Gynecologic Oncology | SAT, April 29*

EUR 350 Breast Cancer | SAT, April 29

CMC Night (Festive Evening)

(extra charge, only in combination with a conference ticket)

EUR 60 FRI, April 28 (Museum of Natural History)

*) Shall we put you on our waiting list?

Please let us know: service@eickeler.org

IMPRINT

Publisher, Layout, Setting

Jörg Eickeler, Beratung · Organisation · Veranstaltung

Neanderstraße 20, 40233 Düsseldorf, Germany

Tel. +49(0)211/688 150-0 (Fax: -50), info@eickeler.org, www.eickeler.org

Images

Cover: Charité Berlin + Wiebke Peitz; Page 5, 13, 24 (top), 25: Charité Berlin;
Page 6: Wiebke Peitz (left); BMG / Thomas Ecke (right); Page 16: Antje Dittmann,
Museum für Naturkunde Berlin; Page 17, 30 (bottom): Henrik Eickeler;
Page 24 (bottom): Carola-Radke, Museum für Naturkunde Berlin;
Further: stock images

WHAT'S MORE

CMC HONORARY EVENT

**Berlin, Graz, Rochester, Tokio -
The Global Dialogue**

Thursday, April 27, 2023 | Start: 7.30 pm

Location:

Chirurgisch-Anatomisches-Trainingszentrum
Wilhelm von Waldeyer-Haus / Campus Charité Mitte
Philippstraße 11, 10115 Berlin

Participation only by invitation!



CMC NIGHT AT THE MUSEUM OF NATURAL HISTORY: SPECIAL DINNER AND MORE

Friday, April 28, 2023 | Start: 8.00 pm

Location:

Museum für Naturkunde
Invalidenstraße 43, 10115 Berlin
Museum of Natural History
500 m from the conference venue

EUR 60 per person (only in combination
with a conference ticket)

Dress code: casual



AWARD CEREMONY

International
Charité Mayo Award
for Outstanding
Engagement in
Gynecological Oncology

On the conference website you can find lots of useful information:
www.charite-mayo.de → Information

TRAVEL


Whether you travel by **airplane**, **public transport** or **car**: We provide you with everything you have to know.

ACCOMMODATION

Here you can find a **list of hotels** near the conference venue.

THE ESSENTIALS AT A GLANCE

- ▶ Berlin Main Station with long- and short-distance trains, suburban trains ("S") and subway ("U") is only 1 km from the Langenbeck-Virchow-Haus. A walk will take you about 15 minutes. If you arrive at Berlin Airport (BER), train S9 at Terminal 1-2 will take you directly to the Main Station.
- ▶ There is a bus stop ("Charité Campus Mitte") right in front of the conference venue! Bus 147 stops here, which also stops at Berlin Main Station (ride time: 4 minutes).
- ▶ Please remark: The conference venue has no car park! There is a public car park at Luisenstraße 49/50 (about 180 m from the conference venue).



■ = Langenbeck-Virchow-Haus

■ = Museum of Natural History

PLATINUM SPONSORS



GOLD SPONSOR



SILVER SPONSORS



*) EUR 30,000

THANK YOU VERY MUCH FOR THE KIND SUPPORT!

SPONSORS

BRONZE SPONSORS



*) EUR 10,000

PREMIUM SPONSORS

POLYTECH

stryker

*

 Bristol Myers Squibb®

sanofi


Institut
AllergoSan

endomag⁺

 Genmab

INTUITIVE

 medac

Medtronic
Engineering the extraordinary

**

 Stemline®
A Menarini Group Company

SPONSORS

 ESTEVE
Advancing health together

 FRESENIUS
KABI
caring for life

 IQVIA

*) EUR 7,500 | **) EUR 5,000

THANK YOU VERY MUCH FOR THE KIND SUPPORT!

COMING UP



ONE-DAY ONLINE MEETING

CMC 2024

DISTILLED

Update on Women's Cancer

APRIL 13, 2024

ONLINE:
LIVE FROM
BERLIN

www.cmc-berlin.de



13th International Charité Mayo Conference



2025 IN BERLIN

www.charite-mayo.de

SCHNEIDEN, STYLEN, SPENDEN.

Unterstützen Sie unser Aktionsjahr
und spenden Sie zugunsten der Deutschen
Stiftung Eierstockkrebs - für mehr Forschung
und eine bessere Aufklärung.

SPENDENKONTO

Stiftung Eierstockkrebs

Einfach mit Ihrer Bank-App
diesen QR-Code scannen:



LASST UNS ÜBER
EIERSTOCKKREBS
SPRECHEN!



Informationen zur Kampagne und
für Betroffene unter:

www.stiftung-eierstockkrebs.de

Eine Initiative von:



FRISEUR:INNEN GEGEN KREBS



Für Innovation in der Onkologie: **Die Zukunft ist orange**

Wir haben die Therapielandschaft der gynäkologischen Onkologie bereits revolutioniert – mit zielgerichteten Therapien für fortgeschrittene Ovarial- und Endometriumkarzinome. Auch in der Hämatologie arbeiten wir an innovativen Optionen, zuletzt zur Behandlung des Multiplen Myeloms.

Das ist erst der Anfang.

Als Pioniere in der Molekular-und Präzisionsmedizin verschreiben wir uns auch langfristig der Entwicklung innovativer, heilender Krebstherapien, beginnend mit unserem umfassenden Studienprogramm. Aktuell forschen wir an über 10 Substanzen in zahlreichen klinischen Studien.

